<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503386</url>
  </required_header>
  <id_info>
    <org_study_id>HJGene_SYat-sen_06_01</org_study_id>
    <nct_id>NCT00503386</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting</brief_title>
  <official_title>A Phase II,Multicenter,Randomized,Double-blind,Cross-over Study of Palonosetron Compared With Granisetron in Prevention of Chemotherapy-induced Nausea and Vomiting in Asian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Jiuyuan Gene Engineering Co. Ltd.,</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Jiuyuan Gene Engineering Co. Ltd.,</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether palonosetron is tolerate and effective in
      preventing chemotherapy-induced nausea and vomiting in oriental population. The study is
      comparing the safety and efficacy of palonosetron with granisetron, a frequently used
      antiemetic in China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Protection from Vomiting (ie.Complete Response in Preventing Vomiting)</measure>
    <time_frame>0-24h, 24-120h , 0-120h following chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Protection from vomiting</measure>
    <time_frame>0-24h,24-120h,0-120h following chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Protection from nausea</measure>
    <time_frame>0-24h,24-120h,0-120h following chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Protection from Both Vomiting and Nausea</measure>
    <time_frame>0-24h,24-120h,0-120h following chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Protection from Both Vomiting and Moderate-to-Severe nausea</measure>
    <time_frame>0-24h,24-120h,0-120h following chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Emetic Episode</measure>
    <time_frame>0-120h following chemotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">144</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>Chemotherapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age ≥ 18 yrs and ＜70 yrs with histologically or cytologically
             confirmed

          -  Malignant disease

          -  Naive or nonnaive to chemotherapy, with a Karnofsky score of ≥ 60

          -  Scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin 60
             ~ 80 mg/m2 on study Day 1

          -  Use of reliable contraceptive measures (for females of childbearing potential) and
             negative pregnancy test at baseline visit

          -  Patients with hepatic, renal, or cardiovascular impairment eligible at the
             investigator's discretion

          -  Patients experiencing, at maximum, mild nausea after previous chemotherapy eligible at
             the investigator's discretion

          -  Predicted life expectancy of ≥ 3 months

          -  Provision of written informed consent.

        Exclusion Criteria:

          -  Inability to understand or cooperate with study procedures

          -  Receipt of investigational drugs ≤ 30 days before study entry

          -  Receipt of other investigational drugs during the course of this study

          -  Seizure disorder or any condition requiring anticonvulsants, sedatives

          -  CNS malignancy or metastasis

          -  Ongoing emesis due to obstruction of digestive tract

          -  Emesis, retching, or Grade 2 or 3 nausea 24 hrs before chemotherapy

          -  Moderate or severe nausea and vomiting after any previous chemotherapy

          -  Scheduled receipt of any chemotherapeutic agent with an emetogenicity level ＞3 during
             study Days 2-5

          -  Scheduled receipt of radiotherapy of the upper abdomen or cranium on study Days 2-5

          -  Scheduled to receive any other drug with potential antiemetic efficacy within 24 h of
             study initiation and throughout day 5

          -  Contraindications to 5-HT3 receptor antagonists

          -  Contraindications to chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tongyu Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fujian Provincial Tumor Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Provincial Tumor Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Affiliated to Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Institute on Thoracic Cancer and Tuberculosis</name>
      <address>
        <city>Beijing</city>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20049561</url>
    <description>Publication: Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Med Oncol. 2010 Jan 5. [Epub ahead of print]</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <keyword>chemotherapy-induced nausea and vomiting</keyword>
  <keyword>acute</keyword>
  <keyword>delayed</keyword>
  <keyword>emesis</keyword>
  <keyword>antiemetics</keyword>
  <keyword>5-HT3 receptor antagonist</keyword>
  <keyword>granisetron</keyword>
  <keyword>palonosetron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

